Sarcoma Oncology Research Center

Santa Monica, California 90404

5 studies enrolling now · 42 studies all time

What they study most

Adenoid Cystic Carcinoma, Advanced Cancer, Advanced Epithelioid Sarcoma, Advanced Malignancies, Advanced Soft Tissue Sarcoma, Advanced Soft-tissue Sarcoma, Advanced Solid Tumor, Advanced Solid Tumors, Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations, Aggressive Fibromatosis, Angiomatoid Fibrous Histiocytoma

Studies at this site

• A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. — Recruiting now
• Metastatic Leiomyosarcoma Biomarker Protocol — Recruiting now
• Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen — Recruiting now
• SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma — Recruiting now
• LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma — Recruiting now
• Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications — Stopped early
• A Study of AL102 in Patients With Progressing Desmoid Tumors — Running, not enrolling
• A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations — Stopped early
• Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma — Stopped early
• A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors — Running, not enrolling
• A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) — Stopped early
• A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors — Stopped early
• Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer — Stopped early
• BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients — Completed
• Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors — Running, not enrolling
• SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma — Running, not enrolling
• Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers — Completed
• Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) — Completed
• A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors — Stopped early
• A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma — Stopped early
• Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies — Completed
• FPA150 in Patients With Advanced Solid Tumors — Stopped early
• Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer — Stopped early
• A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer — Stopped early
• TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations — Stopped early
• Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures — Withdrawn before enrolling
• Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) — Running, not enrolling
• ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma — Status unconfirmed
• Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies — Stopped early
• Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas — Status unconfirmed
• Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy — Completed
• SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes — Completed
• IMX-110 in Patients With Advanced Solid Tumors — Status unconfirmed
• A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer — Completed
• A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa — Completed
• Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer — Completed
• Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) — Completed
• Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers — Completed
• Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors — Completed
• Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) — Stopped early
• Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors — Completed
• CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin — Status unconfirmed